<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

The impact of cytochrome polymorphisms and ABCB1 transporter on treatment response to carbamazepine in Algerian patients with epilepsy

Loading...
Thumbnail Image

Journal Title

Journal ISSN

Volume Title

Publisher

Ecole Supérieure en Sciences Biologique d’Oran

DOI

Abstract

Epilepsy is chronic neurological disorder effecting over 70 million people worldwide. While its prevalence in Algeria was estimated 8.32 per 1000. This study investigated the pharmacogenetics of CBZ therapy in Algerian patients with epilepsy, focusing on polymorphisms in ATP-binding cassette subfamily B member 1 (ABCB1, encoding P-glycoprotein), cytochrome P450 family 3 subfamilies A4 and A5 (CYP3A4, CYP3A5), epoxide hydrolase 1 (EPHX1), and cytochrome P450 family 2 subfamily C member 8 (CYP2C8). A total of 127 Algerian patients with epilepsy were enrolled from Oran University Hospital where all of their demographic and clinical data were collected, genomic DNA was extracted from venous blood using the salting-out method. ABCB1 c.3435C>T was genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), while CYP3A4, CYP3A5, EPHX1, and CYP2C8 variants were analyzed using TaqMan SNP Genotyping Assays. CBZ plasma concentrations were measured by enzyme-multiplied immunoassay technique (EMIT). Statistical analyses included chi-square tests, Kruskal–Wallis tests, logistic regression, and multivariable linear regression. The ABCB1 study revealed no significant associations with CBZ resistance (p=0.1), plasma concentrations (p=0.6-1.0), or adverse reactions (p=0.6-0.9). The CYP3A4/3A5 study demonstrated that CYP3A5 AG carriers required significantly lower doses than AA (p=0.047; beta=-7.34, p=0.017 in multivariate analysis), while CYP3A4 AG carriers required higher doses than GG (beta=+5.85, p=0.008), with combined haplotypes showing highly significant dose associations (p<0.001). The EPHX1/CYP2C8 study showed EPHX1 c.337T>C had a significant gene-dose effect on dose requirements (p=0.036; p=0.043 after excluding enzyme inducers), with CC carriers having 60-70% lower C/D ratios (IRR 0.31-0.38, p<0.001-0.010). CYP2C8 c.416G>A AA homozygotes displayed approximately twofold higher plasma concentrations and C/D ratios (IRR 2.06-2.39, p=0.019-0.045). EPHX1 CT genotype increased dizziness risk (OR 2.98, p=0.021). Neither EPHX1 nor CYP2C8 predicted treatment resistance. This research provides the first comprehensive pharmacogenetic characterization of CBZ therapy in Algerian patients. CYP3A5 and EPHX1 polymorphisms were significantly associated with CBZ dose requirements, supporting implementation of genotype-guided dosing strategies. These findings establish preliminary infrastructure for personalized epilepsy care in Algeria and contribute essential population-specific data to global pharmacogenomics resources.

Description

Keywords

Citation

Endorsement

Review

Supplemented By

Referenced By